IPHA Key Statistics, Chart & Performance
The current stock price of IPHA is 1.74 USD. In the past month the price decreased by -8.08%. In the past year, price decreased by -1.69%.
IPHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About IPHA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
INNATE PHARMA SA-SPONS ADR
117 avenue de Luminy, Bp 30191
Marseille PACA 13009 FR
CEO: Mondher Mahjoubi
Employees: 181
Phone: 33430303030
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What does INNATE PHARMA SA-SPONS ADR do?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Can you provide the latest stock price for INNATE PHARMA SA-SPONS ADR?
The current stock price of IPHA is 1.74 USD. The price decreased by -1.69% in the last trading session.
Does IPHA stock pay dividends?
IPHA does not pay a dividend.
How is the ChartMill rating for INNATE PHARMA SA-SPONS ADR?
IPHA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for IPHA stock?
INNATE PHARMA SA-SPONS ADR (IPHA) currently has 181 employees.
What is INNATE PHARMA SA-SPONS ADR worth?
INNATE PHARMA SA-SPONS ADR (IPHA) has a market capitalization of 160.37M USD. This makes IPHA a Micro Cap stock.
Can you provide the short interest for IPHA stock?
The outstanding short interest for INNATE PHARMA SA-SPONS ADR (IPHA) is 0.37% of its float.
IPHA Technical Analysis
IPHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPHA. Both the profitability and financial health of IPHA have multiple concerns.
IPHA Financial Highlights
Over the last trailing twelve months IPHA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -29.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.46% | ||
| ROE | -894.94% | ||
| Debt/Equity | 11.63 |
IPHA Forecast & Estimates
9 analysts have analysed IPHA and the average price target is 5.7 USD. This implies a price increase of 227.47% is expected in the next year compared to the current price of 1.74.
For the next year, analysts expect an EPS growth of -32.84% and a revenue growth -26.21% for IPHA